|
**Overview**: **STIs-Sexually Transmitted Infections Multiplex Panel****Introduction**: The Sexually Transmitted Infection Multiplex RT-PCR Panel is a diagnostic tool designed to detect sexually transmitted infections using cervical swab or urine samples. In India, STIs affect ~6 percent of adults (higher in urban high-risk groups and rural migrants), with Chlamydia, Gonorrhoea, Trichomonas, Mycoplasma genitalium, HSV, Treponema pallidum, and Gardnerella vaginalis causing cervicitis, urethritis, pelvic inflammatory disease, infertility, and increased HIV transmission. High morbidity from under-testing in rural/low-SES women with vaginal discharge or infertility, limited molecular labs, delayed targeted antibiotics leading to chronic infection or complications. Per microbiology practices aligned with ICMR, National AIDS Control Organisation, and NACO guidelines, the test employs RT-PCR for 9 pathogens over 1-2 days with high sensitivity/specificity, valuable for syndromic management and partner notification. This diagnostic falls under STI screening and targets symptomatic women/men, pregnant women, or high-risk groups, addressing accurate detection to guide specific therapy and prevent sequelae. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling comprehensive STI profiling and reducing transmission/burden. Its swab/urine-based approach ensures reliable multi-pathogen detection.**Other Names**: STI RT-PCR Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/molecular pathology, compliant with 2025 standards.**Historical Milestone**: Multiplex STI PCR standard since 2010s; in India, expanding in NACO centers.**Purpose**: The test assesses 9 parameters including Chlamydia trachomatis to guide STI screening, detect multiple pathogens, inform targeted antibiotics.**Test Parameters**: 1. Chlamydia trachomatis, 2. Neisseria gonorrhoeae, 3. Trichomonas vaginalis, 4. Mycoplasma genitalium, 5. Ureaplasma urealyticum, 6. HSV-1, 7. HSV-2, 8. Treponema pallidum, 9. Gardnerella vaginalis.**Pretest Condition**: No fasting required; patients should have discharge or risk factors.**Specimen**: 1 swab or 10 mL urine in sterile container/transport medium, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: Swab/Urine: 24 hours with proper handling to preserve nucleic acid integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: Swab: 48 hours, Urine: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Swab: â€", Urine: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, partners, pregnancy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected STI including infertility/transmission, benefits of screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using RT-PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low organism load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive pathogen indicates treatable infection, necessitating specialist input.**Specialist Consultation**: Dermatologists or gynecologists should be consulted for management.**Additional Supporting Tests**: Culture, serology for confirmation.**Test Limitations**: Detects nucleic acid only; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, STI Studies India 2023. |
